Journal Club E33: SELECT: Semaglutide for Cardiovascular Outcomes in Obesity Without Diabetes

from AZense Journal Club · host Azense Medical Education

In adults with established cardiovascular disease and obesity but no diabetes, weekly semaglutide reduced major adverse cardiovascular events by 20%. Here is what hospitalists need to know.

Episode metadata supplied by the publisher feed · Published Nov 17, 2025

Embed this episode

Attribution link and audio player

Ready to play

Journal Club E33: SELECT: Semaglutide for Cardiovascular Outcomes in Obesity Without Diabetes

0:00 7:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AZense Journal Club?

This episode is 7 minutes long.

When was this AZense Journal Club episode published?

This episode was published on November 17, 2025.

Can I download this AZense Journal Club episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!